Tedizolid (TR-701): a new oxazolidinone with enhanced potency

被引:65
作者
Kanafani, Zeina A. [1 ]
Corey, G. Ralph [2 ]
机构
[1] American Univ, Beirut Med Ctr, Beirut, Lebanon
[2] Duke Univ, Med Ctr, Durham, NC USA
关键词
oxazolidinone; skin and skin structure infections; Staphylococcus aureus; tedizolid; RESISTANT STAPHYLOCOCCUS-AUREUS; IN-VITRO ACTIVITY; TOREZOLID PHOSPHATE TR-701; PRODRUG TR-701; VANCOMYCIN; ENDOCARDITIS; ENTEROCOCCI; INFECTION; SUSCEPTIBILITY; BACTERIA;
D O I
10.1517/13543784.2012.660250
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Tedizolid phosphate (TR-701) is a new oxazolidinone prodrug that is transformed in the serum into the active drug tedizolid (TR-700). Tedizolid acts by inhibiting protein synthesis and has broad activity against Gram-positive pathogens, including strains that are resistant to linezolid. Areas covered: This review summarizes the currently available data on this new antimicrobial agent. In vitro activity, pharmacokinetics/pharmacodynamics, clinical efficacy and safety are all addressed. Expert opinion: Tedizolid will provide a useful addition to the antimicrobial armamentarium, particularly in complicated skin and skin structure infections, due to its high oral bioavailability and once-daily dosing. The results of future studies will serve to better position tedizolid among the newly approved agents for infections caused by Gram-positive organisms.
引用
收藏
页码:515 / 522
页数:8
相关论文
共 47 条
[21]   TR-700 in vitro activity against and resistance mutation frequencies among Gram-positive pathogens [J].
Jones, Ronald N. ;
Moet, Gary J. ;
Sader, Helio S. ;
Mendes, Rodrigo E. ;
Castanheira, Mariana .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 63 (04) :716-720
[22]   Historical yearly usage of vancomycin [J].
Kirst, HA ;
Thompson, DG ;
Nicas, TI .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (05) :1303-1304
[23]   The site of action of oxazolidinone antibiotics in living bacteria and in human mitochondria [J].
Leach, Karen L. ;
Swaney, Steven M. ;
Colca, Jerry R. ;
McDonald, William G. ;
Blinn, James R. ;
Thomasco, Lisa M. ;
Gadwood, Robert C. ;
Shinabarger, Dean ;
Xiong, Liqun ;
Mankin, Alexander S. .
MOLECULAR CELL, 2007, 26 (03) :393-402
[24]   PLASMID-MEDIATED RESISTANCE TO VANCOMYCIN AND TEICOPLANIN IN ENTEROCOCCUS-FAECIUM [J].
LECLERCQ, R ;
DERLOT, E ;
DUVAL, J ;
COURVALIN, P .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 319 (03) :157-161
[25]   Cellular pharmacokinetics and intracellular activity of torezolid (TR-700): studies with human macrophage (THP-1) and endothelial (HUVEC) cell lines [J].
Lemaire, Sandrine ;
Van Bambeke, Francoise ;
Appelbaum, Peter C. ;
Tulkens, Paul M. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 64 (05) :1035-1043
[26]   Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci [J].
Livermore, David M. ;
Mushtaq, Shazad ;
Warner, Marina ;
Woodford, Neil .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2009, 63 (04) :713-715
[27]   Novel Ribosomal Mutations in Staphylococcus aureus Strains Identified through Selection with the Oxazolidinones Linezolid and Torezolid (TR-700) [J].
Locke, Jeffrey B. ;
Hilgers, Mark ;
Shaw, Karen Joy .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (12) :5265-5274
[28]   In Vivo Pharmacodynamics of Torezolid Phosphate (TR-701), a New Oxazolidinone Antibiotic, against Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus Strains in a Mouse Thigh Infection Model [J].
Louie, Arnold ;
Liu, Weiguo ;
Kulawy, Robert ;
Drusano, G. L. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (07) :3453-3460
[29]   Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia [J].
Mangili, A ;
Bica, I ;
Snydman, DR ;
Hamera, DH .
CLINICAL INFECTIOUS DISEASES, 2005, 40 (07) :1058-1060
[30]   Linezolid: The first oxazolidinone antimicrobial [J].
Moellering, RC .
ANNALS OF INTERNAL MEDICINE, 2003, 138 (02) :135-142